Introduction {#Sec1}
============

Complications of cancer and its treatments are common \[[@CR1]\]. Many patients will experience side effects following chemotherapy, radiotherapy or targeted therapies. These lead to morbidity and mortality as well as increased resource utilisation in the community or hospital setting. Complications of cancer and its treatments are often predictable (fever, diarrhoea, skin reactions and drug-specific effects). Education of patients might help to increase compliance with care pathways \[[@CR2]\] especially if tailored to an individual's needs. In the context of an increasingly digital healthcare system, it is therefore worth considering the role of mobile health applications (mHealth) for clinical care, patient education and safety of treatment.

No standardized definition of mHealth exists, but for the purpose of the Global Observatory for eHealth (GOe), mHealth or mobile health has been defined as 'medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants (PDAs), and other wireless devices' \[[@CR3]\]. There are currently 97,000 mobile health applications, and in 2017, the number of global users for these was thought to be at 3.4 billion patients \[[@CR4]\]. The widespread use of smartphones (80% of patients \[[@CR5]\], 95% of nurse and 99% of doctor \[[@CR6]\]) in the UK means that mHealth applications are potentially accessible by most participants in healthcare: Healthcare professionals use smartphone applications to access risk assessment tools and scoring systems or to recap guidelines. Research on interventions based on mHealth applications suggests that they can be used to alter health related behaviours \[[@CR7]\], such as medication adherence \[[@CR8]\], but economic evidence for their usage is limited \[[@CR9]\].

Patients use applications to get lifestyle advice, dietary information or practice mindfulness, yoga or other sports. Mobile health applications for patients with cancer might track deterioration \[[@CR10]\] and support education and recovery \[[@CR11]--[@CR13]\] and have been suggested as a topic for research \[[@CR14]\]. It is not known how mHealth applications affect patient-reported experience and patient-reported outcome measures. The latter can be generic or cancer specific. Patient-related outcomes measures are thought to be central for the understanding of effectiveness of treatments in cancer, improve patient-provider communication, patient satisfaction \[[@CR15]\], everyday life \[[@CR16]\] and survival \[[@CR17]\].

In order to improve support of patients referred to the local oncology service that covers a large rural and remote area in North Wales, the authors reviewed the literature to identify mHealth application with a peer-reviewed evidence of impact on clinical outcomes that could be deployed in UK practice.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

The review of the literature used the format of a 'Critically appraised topic' (CAT). CATs are standardized summaries which draw together best available evidence to answer questions based on real clinical scenarios \[[@CR18]\]. CATs follow principles of evidence-based medicine in four steps: The authors (1) form a focused and answerable question based on a clinical encounter, (2) search for the best available evidence, (3) critically appraise the evidence for validity and clinical relevance and (4) examine the application of the results to clinical practice and future research.

Search strategy {#Sec4}
---------------

The search question was created in a patient--intervention--comparison--outcomes (PICO) format: 'In patients with cancer (P) have mHealth applications (I) been compared with usual care (C) to examine impact on commonly used clinical outcomes (O)'.

Outcomes that are commonly used in cancer trials include mortality, morbidity, quality of life, usage of hospital beds, number of outpatient appointments or appointments in primary care. The context of care of patients with cancer morbidity related to treatments might be of particular interest.

A literature search was undertaken with the assistance of a research librarian. The following search string was used: (Mobile applications 'OR' Smartphone applications) 'AND' (Cancer 'OR' Neoplasms) followed by further searching using specific outcome measures: ('morbidity' OR 'mortality' OR 'quality of life' OR 'hospital beds' OR 'patient safety' OR 'outpatient appointments' OR 'GP appointments'). Additionally, a search for studies using patient portals was conducted: ("Patient Portals"\[Mesh\]) AND (cancer or neoplasm). Identified papers were searched for further applicable references ('snow balling').

Inclusion and exclusion criteria {#Sec5}
--------------------------------

Study criteria were agreed prior to undertaking the review: Publications up to April 2018 were included. No study pre-dating 2014 was identified. Randomized and non-randomized studies on all types of cancer including haematological malignancies were included. The review included dedicated mobile applications as well as programs that could be used on a smartphone such as web portals.

Non-patient-facing applications, research protocols, studies that did not measure clinical outcomes and studies that reported purely application feasibility were excluded.

Studies were selected by one of the investigators (JO) and confirmed by the second investigator (AA). The papers identified in the search were analysed using the following questions: Does the study address the research question, were the study methods valid in a generic oncology setting and are the results applicable to patients with cancer looked after in a clinical (vs research) setting.

Search terms were applied to Pubmed, Embase, Cochrane library and a national registry of trials ([ClinicalTrials.gov](http://clinicaltrials.gov)).

No funding was received for the undertaking of the review.

Results {#Sec6}
=======

Identified studies {#Sec7}
------------------

The search found 139 abstracts, of which 17 fulfilled inclusion and exclusion criteria (Fig. [1](#Fig1){ref-type="fig"}). Eighty-four studies initially identified did not meet the inclusion criteria as they did not measure a patient-related outcome or were not for direct patient use.Fig. 1PRISMA flow diagram of literature search

The Cochrane Library identified a number of systematic reviews of mobile Health applications but none in the context of cancer care. The national database of clinical trials (ClinicalTrial.Gov) identified 72 trials; 20 of these were marked as 'completed', and two had published results in the peer-reviewed literature \[[@CR19], [@CR20]\].

Seventeen studies met inclusion and exclusion criteria. Sample sizes varied from 12 to 2352 patients with a median of 130 patients. Eleven of the studies had less than 100 participants. Ten of the studies were randomized controlled trials using usual care as their comparator. Patients with breast cancer were the patient group most commonly targeted (6 studies) (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, and [3](#Tab3){ref-type="table"}). Studies examined effects of custom-built smartphone applications and internet portals as well as existing messaging services \[[@CR21]\] and patient portals \[[@CR22]\].Table 1Studies on mHealth applications for patients with cancerAuthor (year)CountryType of applicationNumber of patientsStudy designComparator groupPatient activityApplication functionAljabri D (2018)USAInternet portal2352 patientsRetrospective cohort studyNon-adoptersNot reportedAccess to clinical recordsBasch E (2015)USAInternet portal or kiosk in hospital766 patients; 441 intervention, 325 controlRandomizedUsual careSymptom-checker: chemotherapy-related symptomsAlert: e-mail to nurses for significant or worsening patient-reported symptomsBerry D (2015)USAInternet portal752 patients; 256 intervention group, 261 control groupRandomizedUsual careSymptom-checker & quality of questionnairesEducation: information about symptoms and reportingDenis F (2014)FranceMobile application42 patientsCohort studyClinic appointmentSymptom-checkerAlert: of oncologistFoley N (2016)IrelandMobile application39 patients; 13 intervention group; 26 control groupRandomizedStandard leafletsNoneEducation: information about breast cancerFortier M (2016)USAMobile application12 patientsPilot studyn.a.Symptom-checker: avatar interaction on reporting of painEducation: link to information AlertGolsteijn RHJ (2018)NetherlandsInternet portal478 patients; 249 intervention, 229 controlRandomizedWaiting list controlledLife-style: exercise dataEducation: exercise adviceJibb LA (2017)CanadaMobile application40 patientsCohort studyn.a.Symptom checker: pain measured by questionnaireEducation: link to informationKanera I (2017)NetherlandsInternet portal462 patients; 231 intervention group, 231 control groupRandomizedUsual careLife-style: physical activity & vegetable intake measured by questionnairesEducation: link to educational contentKolb NA (2018)USAAutomated telephone system252 patients; 121 intervention group, 131 control groupRandomizedUsual careSymptom-checkerEducation: self-care strategiesAlert: nurse practitioner reviewRosen KD (2018)USAMobile application112 patients; 57 intervention, 55 controlRandomizedWaiting list controlledEducation: 12-week mindfulness courseSmith SK (2016)USAMobile application31 patientsCohort studyBaselineSymptom-checker: PTSD measured by questionsEducation: link to informationSoto-Pere-De-Celis E (2018)MexicoMobile application40 patientsCohort studyBaselineLife-style: mobility measured by accelerometerAlert: phone call to smartphone for review of toxicitySundberg K (2017)SwedenMobile application130 patients; 66 intervention group, 64 control groupNon-randomized controlled studyHistoric control groupSymptom-checker: psychological distress measured by questionnaireAlert: oncology nurseUhm K (2017)KoreaMobile application356 patients; 179 intervention group, 177 control groupRandomizedExercise brochureLife-style: pedometer measuring activityEducation: goal setting for physical activityWheelock A (2014)USAInternet portal100 patients; 59 intervention group, 41 control groupRandomizedUsual careSymptom-checker: depression & quality of life measured by questionnairesAlert: review by oncology nurseZou Q (2018)ChinaTelephone chat application426 patients; 251 intervention, 175 controlRandomizedUsual careSymptom-checker: anxiety, pain & satisfaction measured by questionnairesContact with oncology teamTable 2Functionality of applications, inclusion criteria, outcome measures and results of studies testing mHealth applications for patients with cancerAuthor (year)Name & function of applicationInclusion criteriaOutcome measuresResultsAljabri D (2018)Existing patient portalAdult patient admitted to hospital with cancer as a primary or secondary diagnosisProvider-reported, in-hospital adverse event; post-discharge emergency department visits and unplanned readmissions within 30 days; satisfaction by Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey.Increased readmission rates among active adaptors of the patient portal.Self-management knowledge scores were higher among adopters vs non-adopters (univariate analyses only)Basch E (2018)**STAR** (Symptom Tracking and Reporting) Web-based interface for self-reporting of common symptoms associated with cancer treatmentPatients with metastatic breast, genitourinary, gynaecologic or lung cancers receiving chemotherapy stratified for experience with computersHealth-related quality of life (HRQoL measured by EQ-5D); emergency room visits, hospitalizations, survival.Patient in the intervention group experienced less decline of HRQoL less frequent admissions to the emergency room, less hospitalization and remained on chemotherapy longer. Effects on HRQoL limited to the computer-experienced subgroup.Berry D (2015)Self-reported online assessment of cancer symptoms: Application facilitating patient self-monitored symptoms, education and coaching on how to report worries to clinicians.Adult patients, any type of cancer or stage, about to start a new treatment for cancer.Symptom distressFatigue, pain and physical function issues were reported significantly more often by patients in the intervention group.Denis F (2014)Sentinel follow-up questionnaire. Email alert sent to oncologist if patient reports red flag symptoms.Lung cancer patients after undergone surgical excision, complete response or detectable but non-progressive lung cancer.Compliance, easiness, anxiety and performances of web application for detecting cancer relapseRelapse detection was on average 5 weeks earlier using sentinel follow-up. Reported better relationship with oncologist and reduced anxiety about follow-up.Foley N (2016)Application containing basic aetiology of breast cancer, treatment and surgical intervention information.Female adult pre-operative patients with breast cancerAnxiety and depression scores prior and post interventionHigher anxiety levels in intervention groups.Fortier M (2016)**Pain buddy**Avatar-guided tablet application including a symptom diary, communication tool and coping strategies for symptom management. Triggers to healthcare providers for severe symptoms.Paediatric patients aged 8--18, diagnosed with cancer, undergoing outpatient cancer treatment. One parent/guardian also invited to participate. No cognitive or developmental delay.Feasibility, symptom frequency and complianceSymptoms were reported and recommended coping strategies utilized. Only 4% of symptoms would have triggered an alert to healthcare professionals, most of these for pain. Good compliance and user satisfaction.Golsteijn RHJ (2018)**OncoActive**Computer-tailored physical activity programProviding personalized feedback with printed materials.Patients and survivors with prostate and colorectal cancer from 17 hospitals throughout the NetherlandsQuestionnaires for self-reported physical activity, fatigue, distress and quality of life. Actigraph for measurement of activityParticipants in the intervention group increased self-reported activity and improved physical functioning, fatigue and depression at 6 months.Jibb LA (2017)**Pain squad+**22-item questionnaire to assess pain. Real-time reporting. Patients were contacted if they reported frequent pain and information was available from the application on how best to manage the pain.Patients aged 12--28, undergoing cancer treatment, at least 2 months from diagnosis. Patients reported pain of 3/10 at least once in week prior to recruitment.Primary: feasibility; secondary: effectiveness: pain intensity, pain interference, health-related quality of life, self-efficacyImprovements in pain intensity and health-related quality of life. Satisfactory acceptability with good adherence by those who completed the study.Kanera I (2017)Web-based self-reporting questionnaires and modules providing education about diet, smoking cessation, physical activity, anxiety, depression and fatigue.Adult patients who had completed primary cancer treatment at least 4 weeks prior. Patients with recurrent cancer and severe medical, psychiatric or cognitive diseases excluded.Physical activity, vegetable consumptionSustained increase in physical activity in the intervention group. Increased vegetable consumption in the intervention group, but results not sustained to 12 months.Kolb NA (2018)**SymptomCare\@Home**Daily symptom monitoring by telephone. Intervention group with automated telephone delivered self-care strategies and alert of nurse practitioner for poor symptom control.Patients beginning chemotherapy with taxane/platinum therapies as a part of a larger trial.Severity, distress and impact on activity of neuropathic painPatients in the intervention group had significantly fewer days with moderate and severe symptoms, fewer days of symptom distress and a trend towards less activity interference.Rosen KD (2018)**Headspace**Commercially available mindfulness applicationWomen aged 25 or more within 5 years post breast cancer diagnosisFunctional Assessment of Cancer Therapy -- Breast (FACT-B), mindfulness, and pain assessments at baseline, during 8 week intervention and at 12 weeks.Participants in the intervention group reported higher quality of life with FACT-B and higher dispositional mindfulness.Sundberg K (2017)**Interaktor**Symptom questionnaire focusing on frequency and distress level, responses triggered red or yellow alerts to an oncology nurse.Adults with localized prostate cancer, eligible for curative radiotherapy, considered physically, psychologically and cognitively fit enough to take part.Symptoms and health-related quality of lifeNo difference within groups in symptoms over time but improvements between intervention and control group. In the control group after radiotherapy worse emotional functioning with more fatigue, nausea, insomnia and urinary symptoms.Smith SK (2016)**Cancer distress coach**PTSD symptom checker with advice on managing symptoms and information on reliable sources of supportLymphoma, breast or prostate cancer patients, 19 years or older, active PTSD symptomsPTSD symptoms, distress, self-efficacy, feasibility, acceptability and perceived usefulness.The majority of patients found the application helpful. Statistically significant reduction is PCL-S score for PTSD symptoms after using the app. No change in self efficacy.Soto-Pere-De-Celis E (2018)**Accelerometer & application**Remote monitoring of daily steps, before and during chemotherapy, with a trigger of \> 15% drop in baseline activity as an indicator of potential chemotoxicity.Patients aged \>65 years, any solid cancer, chemotherapy as first line in either metastatic or recurrent cancer.Primary: feasibility; secondary: association of level of activity with grade of chemotherapy toxicityHigh acceptability of application to patients despite limited interaction with mobile technology and low educational status. Association of low step counts with grade 3 toxicity.Sundberg K (2017)**Interaktor**Symptom questionnaire focusing on frequency and distress level, responses triggered red or yellow alerts to an oncology nurse.Adults with localized prostate cancer, eligible for curative radiotherapy, considered physically, psychologically and cognitively fit enough to take part.Symptoms and health related quality of lifeNo difference within groups in symptoms over time but improvements between intervention and control group. In the control group after radiotherapy worse emotional functioning with more fatigue, nausea, insomnia and urinary symptoms.Uhm K (2017)Pedometer and smartphone app which monitored a prescribed 12-week exercise programme. Quality of life assess at baseline and 12 weeks.Histologically confirmed breast cancer, age 20 to 70 years, completion of primary cancer treatment including surgery, chemotherapy and/or radiotherapy.Activity measurements, self-reported physical activity, quality of lifePhysical function, physical activity, and Quality of Life scores were equally improved in both groups.Wheelock A (2014)**SIS-NET**Three-monthly web-based self-reported symptoms. Remote assessment by a nurse practitioner.Patients with breast cancer after completion of acute treatment or any clinical trial adjuvant treatment (6 months post chemo, 3 months post hormonal therapy or surgery)Time between symptom reporting and evaluation by healthcare professionals, use of healthcare resources.Only 74% of symptoms addressed within less than 3 days.Significantly more symptoms reported by patients in the intervention group. No difference in oncology-related appointments, physician visits or medical tests.Zou Q (2018)Telephone and WeChat applicationSymptomatic adults with uterine myomaHamilton Anxiety Scale before and after treatment, Visual Analogue Scale for pain during the first 24 h after treatment.Patients in the intervention group had less preoperative and postoperative anxiety, less postoperative pain and higher treatment satisfaction.Table 3Compliance with and acceptability of mobile health application and potential sources for bias of the resultsAuthor (year)Compliance with usageAcceptability of interventionBiasAljabri D (2018)Not reportedNot reportedRetrospective analysis of activity found that active inpatients were more likely to be younger, married and non-locals, had higher disease severity, and received medical treatmentBasch E (2015)Not reportedNot reportedComputer-experienced group received weekly e-mail alerts in addition to the self-scoring of symptoms during clinic visits.Berry D (2015)Coaching intervention received in 374/389 patientsNot reportedIntervention group youngerDenis F (2014)82% compliancePatients felt 'reassured by knowing that they were followed by their oncologist using the sentinel follow-up'.Intervention and usual care completed in the same population.Foley N (2016)Not reportedNot reportedSmall group with a significant proportion of participants that had low IT familiarityFortier M (2016)Unable to report due to technical problemsNot reportedNo formal control groupGolsteijn RHJ (2018)Not reportedNot reportedDifferent outcomes in patients with different educational status and cancer type.Jibb LA (2017)Only reported for patients who had no technical problems. Compliance reported at 69%.Satisfactory acceptability.Intervention with significant delay, usage of a second dedicated phone was raised as a problem by participantsKanera I (2017)28% in intervention group used module on physical activityNot reportedHigher drop-out rate at 12 months in the control groupKolb NA (2018)Not reported (4 patients did not use the service)Not reportedInvolvement of a dedicated nurse practitioner who followed up calls in the intervention group might be responsible for the effect.Rosen KD (2018)During a 12-week trial participants logged in to the application on average 18 days.Not reportedHigher drop-out rate in the intervention group limits analysis.Smith SK (2016)Not reported90% of participants endorsed at least moderate satisfaction with the Cancer Distress Coach applicationNo formal control group. Pilot studySoto-Pere-De-Celis E (2018)93% compliance85% found device 'easy to use'No control group in relation to the clinical outcome and small sample size.Sundberg K (2017)Not reportedNot reportedControl group lower level of educationUhm K (2017)Self-assessed activity using a questionnaire based toolLikert scales for overall satisfaction, information satisfaction, continuous use intention and intention to recommend with values from 3.8 to 4.3/5.Different randomisation algorithm in different hospitals, older control groupWheelock A (2014)Not reportedNot reportedCombination of mHealth intervention with dedicated nurse practitionerZou Q (2018)Not reportedNot reportedRandomisation procedure not reported. No data on matching of control and intervention group.

Interventions delivered through mHealth applications {#Sec8}
----------------------------------------------------

Interventions that were delivered in the studies fell into broad categories: (1) delivery of information/education in a digital format \[[@CR23]--[@CR25]\], (2) provision of lifestyle interventions such as mindfulness \[[@CR19]\], exercise \[[@CR26], [@CR27]\] or consumption of vegetables \[[@CR28]\] and (3) symptom scores ranging from pain \[[@CR23]\] to psychological symptoms of post-traumatic stress disorder (PTSD) \[[@CR24]\] and usually linked to a healthcare professional for escalation \[[@CR29]\]. One study looking at detection of lung cancer relapse allowed patients to access follow-up and imaging sooner if concern was raised from reported symptoms \[[@CR30]\].

Reported outcomes {#Sec9}
-----------------

As per our inclusion criteria, only apps which measured a patient-related outcome were included (Table [2](#Tab2){ref-type="table"}).

### Patient symptoms {#FPar1}

Outcomes were heterogeneous, largely focusing on symptoms related to cancer and reporting severity, distress or quality of life impact related to specific symptoms. Quality of life measures included disease specific \[[@CR27]\] or generic \[[@CR31]\] tools.

The main positive clinical outcome from usage of mHealth applications was significant improvement in pain intensity, pain interference and consequentially quality of life \[[@CR23]\]; nausea, fatigue, urinary symptoms and emotional functioning \[[@CR32]\]; fewer days of moderate-severe neuropathic symptoms, distress and activity interference \[[@CR23]\]; reduction in post-traumatic stress disorder symptoms \[[@CR24]\]; reductions in distress \[[@CR33]\] and less severe neuropathic pain compared to usual care \[[@CR34]\] at scheduled outpatient visits. Physical activity improved in two studies \[[@CR20], [@CR28]\]. As a caveat, in several studies, symptoms were more common in the intervention group \[[@CR29], [@CR33], [@CR35]\].

### Treatment toxicity {#FPar2}

A Mexican study established a correlation between reduction in day-to-day mobility and chemotherapy toxicity in geriatric cancer patients \[[@CR26]\]. Symptom scores could be used to optimize treatments \[[@CR31]\].

### Mortality {#FPar3}

One of the studies has subsequently published long-term follow-up data from using a symptom tracking application \[[@CR31]\] about improved mortality in a research letter \[[@CR36]\]. The lack of detail makes evaluation of this publication challenging.

### Health-economic outcomes {#FPar4}

These were not explicitly evaluated, but outpatient appointments and readmissions to hospital provide some surrogate outcomes for financial impact \[[@CR22], [@CR29], [@CR31]\] with one study quoting higher \[[@CR22]\] and one lower hospitalisation rate \[[@CR31]\].

### Adverse effects {#FPar5}

Adverse effects from using the applications were reported in two studies: higher readmission rates in a study of an existing provider portal \[[@CR22]\] and increased anxiety and distress levels in an application with information about breast cancer \[[@CR25]\].

### Others {#FPar6}

A single study focused on the detection of cancer relapse in lung cancer survivors \[[@CR30]\]: the study looking at detection of lung cancer relapse using sentinel questionnaires. On average, relapses were found 5 weeks earlier than the planned follow-up visit, and there was a high sensitivity for detection in relapse, but the intervention did not identify a single relapse that was not also detected by sentinel follow-up.

Methodological considerations {#Sec10}
-----------------------------

Studies had clearly documented inclusion criteria and methodology. All applications using symptom reporting used validated and peer-reviewed scales. While ten of the studies were randomized, for obvious reasons none of them were blinded. Education status and familiarity with internet/mobile technology improved outcomes \[[@CR31]\] in one study but not in another \[[@CR26]\].

Patients used the interventions in varying amounts, but little data were available on the 'dosage' of application usage. Increased usage might perceivably lead to improved outcomes. A 'prescribed dose' of intervention would facilitate evaluation but would be unrealistic as patients will experience symptoms in varying amounts and will therefore need their intervention in varying amounts \[[@CR23]\]. Some measure of compliance was included in most studies whereas acceptability was only formally assessed in three studies (Table [3](#Tab3){ref-type="table"}).

Applicability of results to patients undergoing routine oncology care {#Sec11}
---------------------------------------------------------------------

Studies identified covered a wide range of ages and demonstrated that both young people and the older generation were comfortable using apps. Some of the used measurement tools referred to a specific malignancy, and extrapolation of results does therefore need to be with caution. Variation in sample size means that results from studies with smaller patient groups might be context sensitive and not be applicable without further testing in other clinical settings.

While self-reported outcomes may be subject to some recall bias \[[@CR28]\], many of the applications allowed for in the moment reporting \[[@CR23], [@CR37]\] which is likely to have less recall bias than waiting to inform a medical practitioner in an outpatient or clinic setting.

Safety aspects {#Sec12}
--------------

Several of the applications described alert systems which informed a healthcare professional if further intervention was required, potentially improving patient safety and increasing communication between patient and healthcare providers. One application facilitated discussion between healthcare providers and patient by educating the patient on how best to communicate their concern prior to a clinic appointment \[[@CR33]\]. Response to new symptoms was at times delayed: In 'SIST-net' 74% percent of new symptoms reported by patients were addressed by a nurse practitioner in under three working days; this was below the pre-set target of 90%, thus highlighting potential workload implications and the need to put robust failsafe mechanism in place to follow up reported symptoms \[[@CR29]\].

Discussion {#Sec13}
==========

The authors have identified a small number of mHealth applications that have been examined in clinical studies with a randomized or non-randomized control group. Studies identified were aimed at a range of different cancers and age groups. Positive impact was largely limited to improved symptom control, but several studies reported increased symptoms. Data on other outcomes including health economic measures were limited.

Our search is limited by several factors: In patients with cancer changes in clinical status, morbidity and mortality can be expected within months, but the sample size of most studies might have precluded significant numbers within the study duration. Only one of the studies examined impact on mortality \[[@CR36]\]; however, since the longest study was only conducted for 12 months, there is at current lack of long-term data.

Friends, family, and other carers are often able to identify deviation from a patient's normal status as a first step to facilitate calls for help. Only one study 'pain buddy', an avatar-based symptom dairy/pain management application, invited a family member to also engage with the application, so this is a potentially unique or underexplored feature \[[@CR37]\].

The majority of studies identified were randomized controlled trial. Given the fast pace of innovation in digital technology, this might not be the best methodology to evaluate impact \[[@CR38]\]. Smartphone applications are only one of the new digital ways to provide care with smart watches \[[@CR39], [@CR40]\] and telehealth \[[@CR41], [@CR42]\] offering alternatives to traditional models of care.

The reasons for the limited evidence for mHealth applications in cancer might be complex: mHealth applications are a relative new addition to the armamentarium of clinicians, but safety implications are potentially considerable. The novelty means that principles of design and implementation are not as clear as those used for pharmacological interventions. Mobile applications for medical purposes require compliance with regulations and the obligation to updating information. A review of mHealth applications for patients with cancer in Spain found that only half had been developed by healthcare organisations \[[@CR48]\]. The potential lack of clinical input into the development might be one reason for limited clinical impact despite the considerable promise of applications to monitor toxicity \[[@CR26]\] or even adjust chemotherapy drug dosing for safety impact \[[@CR49]\].

The present search identified registered trials that might help for further insights into the impact of mHealth interventions in the near future: eRapid is a system for patients to 'self-report and manage adverse events online during and after cancer treatment'. The platform has been developed with patients \[[@CR43], [@CR44]\]. Field testing has been completed \[[@CR45]\], and the related randomized controlled trial is powered against symptom control but will include the number of hospital, primary care, and community contacts.

The eSMART trial will study an application for symptom management in a European multi-centre study to assist patients receiving chemotherapy for breast, colorectal, or haematological cancer \[[@CR46]\]. PRISMS will attempt a similar intervention in an Australian trial of patients with haematological malignancies \[[@CR47]\].

Patients with cancer are in principle willing to embrace application assisted care \[[@CR50]\]: A survey of patients with prostate cancer found that out of 375 participants, about half were willing to use a cancer care--assisted app and 72% of these said data protection/pseudonymisation was important. A third of the participants who were not willing to use an application cited that secure data transfer and data storage were a concern.

The mHealth application opens the possibility of round-the-clock care where e-alerts generated from the app can be monitored and acted upon by a member of the cancer specialist team. In practice, out-of-hours services might not be robust enough to accommodate round-the-clock monitoring in many areas. While the ability for applications to facilitate improved communication and red flag alerting with health services, care needs to be made to ensure patients understand that the app is not a replacement for usual care but an adjunct \[[@CR51]\].

MHealth interventions work in part through changing communication patterns between patients and their care network. Randomized controlled trials might not be the most suitable way to test complex multi-faceted interventions that are difficult to blind. Studies using patient registries might provide an alternative way to evaluate this type of intervention \[[@CR52], [@CR53]\].

Conclusions {#Sec14}
===========

The CAT review was based on service consideration in the unit of the authors that provides care for patients in rural and remote areas in North Wales: This review found only a small number of studies measuring outcomes relevant to the PICO question despite a broad search string and multiple databases. Many of the screened studies looked exclusively at the design, feasibility and acceptance of mobile health applications, but there was a significant lack of evidence for the efficacy of utilizing patient-facing applications to improve clinically relevant outcomes. More in-depth studies are needed with larger cohorts to fully evaluate the impact of applications to improve patient outcomes.
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